Genzyme Announces Agreement to Sell Genetic Testing Business to LabCorp

15-Sep-2010 - Genzyme Corporation announced that it has entered into an asset purchase agreement under which Laboratory Corporation of America Holdings (LabCorp) will acquire Genzyme Genetics for $925 million in cash. Under the terms of the agreement, LabCorp will purchase the business in its entirety, ...

Genzyme to Build New R&D Center in Beijing

Environmentally Responsible Site to Significantly Increase Company's Presence in China

25-Apr-2008 - Genzyme Corp. announced that it will build a major new research and development center in Beijing. The initiative is an important element in Genzyme's ongoing global expansion and commitment to establishing a long-term presence in China. The new facility will be used for research and development ...

Genzyme Launches New Diagnostic Test for Common Blood Cancer

p53 Mutation Analysis Offers Critical Prognostic and Predictive Information for B-Cell Chronic Lymphocytic Leukemia

31-Jul-2006 - Genzyme Corporation announced the availability of its p53 Mutation Analysis for B-cell chronic lymphocytic leukemia (B-CLL). P53 is a tumor suppressor gene that stops cell division when DNA damage is present. When the p53 gene does not function normally, genetic mutations that can occur in ...

Genzyme Releases Two New Molecular Tests for Acute Myelogenous Leukemia

Tools Improve Treatment Management of AML Patients

19-May-2006 - Genzyme Corporation announced the availability of two new molecular tests for acute myelogenous leukemia (AML) with the launch of FLT3 Mutation Analysis and WT1 RQ-PCR. FLT3 mutations are considered a prognostic indicator of poor survival and response to standard chemotherapies. The WT1 RQ PCR ...

Genzyme Launches Key Test To Monitor Gleevec Resistance

Two Additional Personalized Medicine Tests Also Available

13-Feb-2006 - Genzyme Corporation announced the availability of an important new test to monitor drug resistance in chronic myeloid leukemia (CML) patients who are treated with Gleevec® (imatinib mesylate). Despite high response rates to Gleevec, approximately four to five percent of patients who were ...

Genzyme Receives Waiver for OSOMR Trichomonas Rapid Test

13-Apr-2005 - Genzyme Corporation announced that it has received a Clinical Laboratory Improvement Act (CLIA) waiver from the U.S. Food and Drug Administration for its OSOM® Trichomonas Rapid Test. This waiver significantly expands the number of clinics and doctors' offices that can use the test, which aids in ...